NCT02569541View on ClinicalTrials.gov

Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 17, 2017

Study Completion Date

February 21, 2019

Conditions
Refractory Bone or Joint Infections
Interventions
DRUG

sodium fusidate

Trial Locations (19)

19041

Haverford

19107

Philadelphia

19355

Malvern

21218

Baltimore

28207

Charlotte

33321

Tamarac

40202

Louisville

44195

Cleveland

45219

Cincinnati

48202

Detroit

59701

Butte

62703

Springfield

77030

Houston

90502

Torrance

91432

Sylmar

91773

San Dimas

92708

Fountain Valley

02111

Boston

08244

Somers Point

Sponsors

Lead Sponsor

Arrevus Inc.
All Listed Sponsors
lead

Arrevus Inc.

INDUSTRY

NCT02569541 - Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections | Biotech Hunter | Biotech Hunter